BOLTON SECURITIES CORPORATION’s Ultragenyx Pharmaceutical RARE Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$376K	Buy	+25,000	New	+$600K	0.01%	687

Other funds holding RARE

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's RARE Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION opened a new position in Ultragenyx Pharmaceutical (RARE) in Q3 2026: 25,000 shares worth $376K. The stake represents 0.01% of the portfolio and ranks #687 among its holdings.

132 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

BOLTON SECURITIES CORPORATION held 25,000 shares of Ultragenyx Pharmaceutical worth $376K as of Q3 2026.
Ultragenyx Pharmaceutical was a new BOLTON SECURITIES CORPORATION position in Q3 2026.
Ultragenyx Pharmaceutical made up 0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q3 2026, its #687 holding.
132 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.